SynthesisInternational journal of molecular sciences2025
Antisense Versus Antigene in the Computer-Aided Design of Triplex-Forming Oligonucleotides (TFO): Insights from a Dual-Method Review, Combining Bibliometric and Systematic Review.
Synthesis in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
This study offers a comprehensive overview of the scientific landscape surrounding computer-aided drug design (CADD) for triplex-forming oligonucleotides (TFOs) within antisense and antigene therapeutic strategies. A dual-method approach was used, combining bibliometric mapping of 6154 Scopus-indexed articles (1980-2023) to identify publication trends and intellectual networks, with a PRISMA 2020-guided systematic review of 62 experimental studies (2015-2024) from Scopus and Web of Science, after removing duplicates using AteneaSIRES. Results show the strong dominance and clinical maturity of antisense strategies, supported by 18 FDA/EMA/MHLW-approved drugs, whereas antigene approaches remain technically limited and underdeveloped. Antigene research has focused on triplex stability modeling and biophysical feasibility but faces challenges with poor biochemical stability, limited in vivo validation, and outdated methods. Meanwhile, antisense design benefits advanced CADD pipelines, including molecular dynamics and docking modeling. Based on these insights, we propose a practical, narrative roadmap as a methodological guide: integrating proven antisense design practices and providing actionable strategies to enhance antigene research, ultimately increasing the translational potential of therapeutic TFOs with solid mechanistic and translational support.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.